With the recent convocation of the 119th Congress, a change in administration, and resignation of USPTO Director Vidal, pharmaceutical patent ...

Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Eton has secured a patent from the USPTO for its ET-600 product candidate’s desmopressin oral solution formulation for ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Obtaining regulatory approval for small-molecule therapeutics continues to be an arduous and expensive process ... crystals can expand patent protection and may help pharmaceutical companies ...

ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO ...

The patent expires in 2044 and is ... risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in ...

ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has ...